Antibody Information

General Information of This Antibody
Antibody ID
ANI0OWWUT
Antibody Name
Indatuximab (C226S + C229S)
Antibody Type
Monoclonal antibody (mAb)
Antibody Subtype
Chimeric IgG4-kappa
Antigen Name
Syndecan-1 (SDC1)
  Antigen Info 
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
Half nBT062-DM4 [Investigative]
 ADC Info 
Discovered Using Patient-derived Xenograft Model
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Tumor Growth Inhibition value (TGI) ≈ 100.00% (Day 56) Positive CD138 expression (CD138+++/++)
Method Description
Half nBT062-DM4 (4 mg/kg/week for three injections in total) induces efficient tumor cell killing in models of MAXF1322 mammary carcinoma cells with CD138 expression with high expression.
In Vivo Model Breast cancer PDX model (PDX: MAXF 1322)
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50)
0.085 nM±0.005 nM
Positive CD138 expression (CD138+++/++)
Method Description
WT nBT062-DM4, stable nBT062-DM4, half nBT062-DM4 or bispecific nBT062-natalizumab-DM4 were added to the cells. Cells were incubated and after 5 days the viability was determined using the WST-1 cell proliferation assay.
In Vitro Model Plasma cell myeloma NCI-H929 cells CVCL_1600
References
Ref 1 Functional relevance of in vivo half antibody exchange of an IgG4 therapeutic antibody-drug conjugate. PLoS One. 2018 Apr 19;13(4):e0195823. doi: 10.1371/journal.pone.0195823. eCollection 2018.

If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.